This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Trial of 6% HES130/0.4

This study has been completed.
Sponsor:
Information provided by:
Fresenius Kabi
ClinicalTrials.gov Identifier:
NCT01010022
First received: November 6, 2009
Last updated: March 9, 2011
Last verified: March 2011
  Purpose
The study shall evaluate the efficacy and safety of two different hydroxyethyl starch solutions (artificial colloids 6% HES130/0.4 and 6% HES70/0.5, Salinhes®) for intra-operative therapy of hypovolemia and maintenance of circulating blood volume in patients undergoing orthopedic surgery. The primary efficacy endpoint will be the required volume of colloid solution infused from start until end of surgery. It is the aim of the clinical trial to demonstrate that comparable volumes of colloid solution are used between treatment groups.

Condition Intervention Phase
Hypovolemia Hemorrhage Drug: 6% hydroxyethyl starch 130/0.4 Drug: 6% hydroxyethyl starch 70/0.5 (Salinhes®) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Examination of Safety and Efficacy of 6% Hydroxyethyl Starch 130/0.4 vs. 6% Hydroxyethyl Starch 70/0.5 in Patients Undergoing Orthopedic Surgery - a Double-blind, Parallel Group, Comparative, Multi-centre Phase III Study

Resource links provided by NLM:


Further study details as provided by Fresenius Kabi:

Primary Outcome Measures:
  • Volume of colloid solution infused during investigational period (= intra-operatively) [ Time Frame: Intra-operatively ]

Secondary Outcome Measures:
  • Fluid input [ Time Frame: From immediately before induction of anesthesia until 48 hours after end of surgery ]
  • Fluid output [ Time Frame: From immediately before induction of anesthesia until 48 hours after end of surgery ]
  • Fluid balance [ Time Frame: From immediately before induction of anesthesia until 48 hours after end of surgery ]
  • Hemodynamics [ Time Frame: From immediately before induction of anesthesia until 48 hours after end of surgery ]
  • Co-administration of vasoactive drugs [ Time Frame: From enrolment until 48 hours after end of surgery ]

Enrollment: 64
Study Start Date: November 2009
Study Completion Date: November 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
Drug: 6% hydroxyethyl starch 130/0.4
Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
Active Comparator: 2
Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
Drug: 6% hydroxyethyl starch 70/0.5 (Salinhes®)
Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)

  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with an expected blood loss of ≥ 300 mL undergoing elective orthopedic surgery
  • Patients with a body weight (BW) ≥ 50 kg

Exclusion Criteria:

  • Known or suspected allergy to hydroxyethyl starch, including its ingredients (inclusive corn) and related drugs
  • ASA classification ≥ IV
  • Renal disease (serum creatinine ≥ 2mg/dL)
  • Known bleeding disorders
  • Congestive heart failure
  • Fluid overload
  • Intracranial bleeding
  • Severe hypernatremia
  • Severe hyperchloremia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01010022

Locations
Japan
Sapporo Medical University, School of Medicine
Sapporo, Hokkaido, Japan, 060-8543
Kyushu University, Graduate School of Medical Sciences
Fukuoka, Japan, 812-8582
Kobe University Graduate School of Medicine
Kobe, Japan, 650-0017
Okayama University
Okayama, Japan, 700-8558
Osaka University Graduate School of Medicine
Osaka, Japan, 565-0871
Keio University School of Medicine
Tokyo, Japan, 160-8582
Tokyo Women's Medical University
Tokyo, Japan, 162-8666
Sponsors and Collaborators
Fresenius Kabi Japan
Investigators
Study Chair: Akiyoshi Namiki, MD, PhD Emeritus Professor, Sapporo Medical University
  More Information

Responsible Party: Tsuneo Tsubaki, PhD, Pharm.D., Fresenius Kabi Japan K.K.
ClinicalTrials.gov Identifier: NCT01010022     History of Changes
Other Study ID Numbers: HS-13-02-JP
Study First Received: November 6, 2009
Last Updated: March 9, 2011

Keywords provided by Fresenius Kabi:
hypovolemia
surgical blood loss
orthopedic procedures
Treatment of reduced circulating blood volume (hypovolemia) including massive hemorrhage

Additional relevant MeSH terms:
Hemorrhage
Hypovolemia
Pathologic Processes
Pharmaceutical Solutions
Hydroxyethyl Starch Derivatives
Plasma Substitutes
Blood Substitutes

ClinicalTrials.gov processed this record on June 23, 2017